Talking about pancreatic cancer means facing one of the most difficult diagnoses to accept, both for those who receive it and for those who accompany a loved one along the treatment path. It is a silent tumor, often discovered late, which even today leaves few therapeutic possibilities. For this reason, when new and solid signals arrive from research, it is worth stopping, understanding and reporting carefully, without sensationalism but also without cynicism.
In recent days, attention has been focused on a study led by the Spanish scientist Mariano Barbacid, one of the most authoritative names in European oncology research, which opens up interesting scenarios against the most widespread and aggressive form of pancreatic cancer.
A scientific discovery born from years of work
The research was conducted at the Centro Nacional de Investigaciones Oncológicas (CNIO) in Madrid and published in the prestigious journal Proceedings of the National Academy of Sciences. At the center of the study is pancreatic ductal adenocarcinoma, responsible for the majority of cases and known for its resistance to traditional therapies.
The Barbacid team has developed a combined therapy based on three drugs, designed to act simultaneously on different biological mechanisms that allow the tumor to grow and defend itself. Instead of hitting a single target, as is often the case, the approach aims to “close multiple doors together,” reducing the ability of tumor cells to adapt and survive.
The results observed in the preclinical study phase were defined by the researchers themselves as particularly encouraging, both for the effectiveness of the treatment and for its tolerability profile. An aspect that is anything but secondary, especially when it comes to quality of life.
Why this research is important
It is essential to clarify this immediately: we are not faced with a cure that is already available, nor an immediate solution for patients. The scientists themselves urge caution and explain that more time, checks and clinical studies will be needed before understanding whether these results can be translated into therapies for humans.
Yet, the value of this research remains enormous. Pancreatic cancer has one of the lowest survival rates ever and, in Spain alone, causes over 10,000 deaths every year. In this context, being able to demonstrate that it is possible to block the disease effectively and stably represents a change of perspective, not an empty promise.
It is no coincidence that Barbacid is leading this work, the scientist who already in the 1980s contributed to the discovery of the RAS gene, today considered one of the main causes of the development of many solid tumors, including pancreatic cancer. A common thread that runs through decades of rigorous research, far from the spotlight but close to people.
You might also be interested in:
